Advertisement
Advertisement
ARGX
argenx SE - ADR
663.76
USDSponsored
-20.74
-3.03%
Mar 20, 15:59 UTC -4
Closed
After-Market
663.72
-0.04
-0.01%
ARGX Earnings Reports
Positive Surprise Ratio
ARGX beat 22 of 40 last estimates.
55%
Next Report
Date of Next Report
May 07, 2026
Estimate for Q1 26 (Revenue/ EPS)
$1.35B
/$5.84
Implied change from Q4 25 (Revenue/ EPS)
+1.86%
/-27.18%
Implied change from Q1 25 (Revenue/ EPS)
+66.80%
/+126.36%
argenx SE - ADR earnings per share and revenue
On Feb 26, 2026, ARGX reported earnings of 8.02 USD per share (EPS) for Q4 25, beating the estimate of 6.23 USD, resulting in a 28.67% surprise. Revenue reached 1.32 billion, compared to an expected 1.32 billion, with a 0.31% difference. The market reacted with a +1.82% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 11 analysts forecast an EPS of 5.84 USD, with revenue projected to reach 1.35 billion USD, implying an decrease of -27.18% EPS, and increase of 1.86% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
$0.09
Actual
$0.05
Surprise
-45.53%
XOMA Royalty Corporation Common Stock
Report Date
Mar 18, 2026 For Q4 25
Estimate
-$0.15
Actual
$0.12
Surprise
+175.90%
Cellectis S.A. - ADR
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.26
Actual
-$0.26
Surprise
+1.78%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
Eledon Pharmaceuticals, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.20
Actual
-$0.10
Surprise
+51.78%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Mar 18, 2026 For Q4 25
Estimate
$0.00
Actual
-$0.07
Surprise
-1472.55%
Milestone Pharmaceuticals Inc. Common Shares
Report Date
Mar 20, 2026 For Q4 25
Estimate
-$0.16
Actual
-$0.16
Surprise
+1.96%
Artiva Biotherapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.84
Actual
-Surprise
-
Spruce Biosciences, Inc. Common Stock
Report Date
Apr 13, 2026 For Q4 25
Estimate
-$8.14
Actual
-Surprise
-
Pelthos Therapeutics Inc.
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$4.21
Actual
-$2.83
Surprise
+32.82%
FAQ
What were argenx SE - ADR's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, argenx SE - ADR reported EPS of $8.02, beating estimates by 28.67%, and revenue of $1.32B, 0.31% above expectations.
How did the market react to argenx SE - ADR's Q4 2025 earnings?
The stock price moved up 1.82%, changed from $796.00 before the earnings release to $810.51 the day after.
When is argenx SE - ADR expected to report next?
The next earning report is scheduled for May 07, 2026.
What are the forecasts for argenx SE - ADR's next earnings report?
Based on 11
analysts, argenx SE - ADR is expected to report EPS of $5.84 and revenue of $1.35B for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement